Estrella Immunopharma Inc (ESLA)

$2.27 +0.07 (3.18%)
Market Cap 81.55M
Revenue (ttm) 0.00
Net Income (ttm) -7.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 129,200
Avg Vol 300,062
Day's Range N/A - N/A
Shares Out 37.07M
Stochastic %K 27%
Beta 0.52
Analysts Strong Sell
Price Target $16.00

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 318 9098
Address:
5858 Horton Street, Suite 370, EmeryVille, United States
_www_larval_com_
_www_larval_com_ Nov. 12 at 8:52 PM
$CYPH 7%[387%] $ESLA 4%[-16%] $CMCT 4%[93%] $FTCI 3%[47%] $WLDS 3%[39%] most notable movement into the final minutes of trading.
0 · Reply
WendyMorell1077
WendyMorell1077 Nov. 6 at 4:04 PM
$ESLA attracts attention as electric and automation themes rise. AITX demonstrates sector leadership through next-generation perimeter monitoring technologies.
0 · Reply
Pb1782
Pb1782 Nov. 4 at 2:51 PM
$ESLA
0 · Reply
StockScanners
StockScanners Nov. 4 at 2:05 AM
$ESLA keep watch if this holds above 2.77
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 3 at 11:07 PM
$ESLA
0 · Reply
Pb1782
Pb1782 Nov. 3 at 9:16 PM
$ESLA
0 · Reply
topstockalerts
topstockalerts Nov. 3 at 8:51 PM
$ESLA Strong action today..
0 · Reply
AlGo88
AlGo88 Nov. 3 at 7:44 PM
$ESLA nice
0 · Reply
mibulldog
mibulldog Nov. 3 at 6:54 PM
$ESLA Up 220% in last 3 months, positive results for clinical trial of EB103. Only 314 watching?? Need to get more eyes on this.
0 · Reply
_luke637
_luke637 Nov. 3 at 5:55 PM
$ESLA
0 · Reply
Latest News on ESLA
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Nov 3, 2025, 8:00 AM EST - 11 days ago

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Oct 6, 2025, 8:00 AM EDT - 5 weeks ago

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Jun 3, 2025, 8:00 AM EDT - 5 months ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

May 29, 2025, 8:01 AM EDT - 6 months ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Mar 5, 2025, 8:00 AM EST - 9 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 21, 2025, 8:30 AM EST - 9 months ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Feb 19, 2025, 4:46 PM EST - 9 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Sep 27, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 14, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Estrella Immunopharma Nears Completion Of SPAC Listing

Sep 19, 2023, 1:30 AM EDT - 2 years ago

Estrella Immunopharma Nears Completion Of SPAC Listing

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

_www_larval_com_
_www_larval_com_ Nov. 12 at 8:52 PM
$CYPH 7%[387%] $ESLA 4%[-16%] $CMCT 4%[93%] $FTCI 3%[47%] $WLDS 3%[39%] most notable movement into the final minutes of trading.
0 · Reply
WendyMorell1077
WendyMorell1077 Nov. 6 at 4:04 PM
$ESLA attracts attention as electric and automation themes rise. AITX demonstrates sector leadership through next-generation perimeter monitoring technologies.
0 · Reply
Pb1782
Pb1782 Nov. 4 at 2:51 PM
$ESLA
0 · Reply
StockScanners
StockScanners Nov. 4 at 2:05 AM
$ESLA keep watch if this holds above 2.77
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 3 at 11:07 PM
$ESLA
0 · Reply
Pb1782
Pb1782 Nov. 3 at 9:16 PM
$ESLA
0 · Reply
topstockalerts
topstockalerts Nov. 3 at 8:51 PM
$ESLA Strong action today..
0 · Reply
AlGo88
AlGo88 Nov. 3 at 7:44 PM
$ESLA nice
0 · Reply
mibulldog
mibulldog Nov. 3 at 6:54 PM
$ESLA Up 220% in last 3 months, positive results for clinical trial of EB103. Only 314 watching?? Need to get more eyes on this.
0 · Reply
_luke637
_luke637 Nov. 3 at 5:55 PM
$ESLA
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 4:24 PM
D. Boral Capital has adjusted their stance on Estrella Immunopharma ( $ESLA ), setting the rating to Buy with a target price of 16.
0 · Reply
hsfjhv
hsfjhv Nov. 3 at 3:01 PM
$ESLA where is everyone? 100% complete response (CR) rate at Month 1 in all evaluable patients treated
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 28 at 7:58 PM
$VRA 4%[20%] $DVLT 4%[0%] $FUSE 4%[21%] $ESLA 3%[10%] $CLIK 3%[-28%] most notable movement into the final minutes of trading.
0 · Reply
Stocksiren
Stocksiren Oct. 24 at 3:34 PM
$ESLA
0 · Reply
StockScanners
StockScanners Oct. 24 at 12:50 AM
$ESLA reached 2.37
0 · Reply
Stocksiren
Stocksiren Oct. 23 at 11:18 AM
$ESLA
0 · Reply
StockScanners
StockScanners Oct. 23 at 12:48 AM
$ESLA keep watch if this holds above 2.15
0 · Reply
MoEx
MoEx Oct. 22 at 9:53 PM
My list $AREB $APLT $ESLA $CCO 👌✅ wait and watch !
0 · Reply
Stocksiren
Stocksiren Oct. 22 at 6:54 PM
$ESLA
0 · Reply
MarketMasterMind
MarketMasterMind Oct. 22 at 5:35 PM
$ESLA adding some 🤑Ⓜ️
0 · Reply
topstockalerts
topstockalerts Oct. 22 at 5:28 PM
$ESLA It is ready to run..
0 · Reply
AlGo88
AlGo88 Oct. 22 at 4:53 PM
$ESLA solid
0 · Reply